Sweeping 100% tariffs on imported brand-name drugs are forcing the entire pharmaceutical industry to rebuild its supply chain on American soil. The companies in this group are already set up to benefit from that transition right now.
Industry leaders have pledged an estimated $400 billion in capital expenditure to comply with new federal requirements. That kind of investment doesn't happen quietly, and the businesses best placed to absorb it are right here in this group.
Professional analysts have specifically identified domestic CDMOs, distributors, and established biopharma names as the primary beneficiaries of this policy shift. This group brings all of those opportunities together in one place.
This basket's total market capitalisation is $NaN and is anchored by very large-cap pharmaceutical and healthcare stocks, tilting it toward stability and broader market correlation.
LLY: $883.95B
PFE: $161.09B
MRK: $298.84B
The Trump administration's sweeping 100% tariffs on imported brand-name drugs are forcing a historic shift in how and where medicines are made. This creates a powerful tailwind for companies already operating on American soil. Our analysts believe the businesses in this group are best placed to capture the surge in domestic investment and manufacturing activity that follows.
This group spans the full US healthcare value chain, from contract drug manufacturers and bioprocessing suppliers to large-scale distributors and established biopharma giants. These are not speculative bets but established businesses with real infrastructure already in place. The policy shift does, however, bring uncertainty for companies still reliant on overseas supply chains, so the landscape remains dynamic.
Each stock in this group was handpicked by professional analysts for its direct connection to the reshoring of US pharmaceutical manufacturing. Whether it is a contract manufacturer ready to absorb new demand, a distributor critical to a localized supply chain, or a biopharma giant with deep domestic roots, every company here has a credible reason to benefit from this major policy shift.
The Trump administration is implementing sweeping 100% tariffs on imported brand-name drugs to force pharmaceutical companies into producing their medicines stateside. This aggressive policy shift creates a highly lucrative environment for US-based contract manufacturers and domestic healthcare supply chain operators as global drugmakers rush to reshore their operations.
4์ 4 ๊ฒ์
+5
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
์ด ์์ฐ๋ค์ ํฌ์ํ๋ค๋ฉด:
12๊ฐ์ ํ ์์ ๊ฐ์น:
+9.31%
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly & Co
LLY
ํ์ฌ๊ฐ
$1,294.29
Eli Lilly's massive ongoing investments in US-based manufacturing facilities perfectly align with the new regulatory push to keep drug production with...
Eli Lilly's massive ongoing investments in US-based manufacturing facilities perfectly align with the new regulatory push to keep drug production within American borders.
Pfizer
PFE
ํ์ฌ๊ฐ
$29.40
With significant domestic manufacturing capabilities, Pfizer has a distinct home-field advantage to scale US production of its proprietary medicines w...
With significant domestic manufacturing capabilities, Pfizer has a distinct home-field advantage to scale US production of its proprietary medicines without tariff penalties.
Merck & Co.
MRK
ํ์ฌ๊ฐ
$140.82
Merck's substantial US-based manufacturing footprint allows it to mitigate import tariffs and capitalise on the administration's aggressive push for d...
Merck's substantial US-based manufacturing footprint allows it to mitigate import tariffs and capitalise on the administration's aggressive push for domestic drug production.
Join Nemo FREE today and unlock every stock
60์ด๋ฉด ์ถฉ๋ถํฉ๋๋ค.
์ ๋๋ฆฌ์คํธ๋ค์ ์ด ๊ทธ๋ฃน์ ์์ฐ์ด ํฅํ 1๋ ๊ฐ ํ๊ท 9.31% ์ฑ์ฅํ ๊ฒ์ผ๋ก ์์ํฉ๋๋ค.
์ด ๊ทธ๋ฃน์ ์์ฐ 15๊ฐ ์ค 12๊ฐ๊ฐ ์ ๋ฌธ ์ ๋๋ฆฌ์คํธ๋ก๋ถํฐ ๋งค์ ์๊ฒฌ์ ๋ฐ์์ต๋๋ค.
์ด ๋ฐ์ค์ผ์ ์ ์ฒด ์คํ ๋ฆฌ๋ฅผ ํ์ธํ์ธ์. ๋ฆฌ์คํฌ์ ์ ์ฌ๋ ฅ์ ๋ค๋ฃฌ ์์ธ ๊ธฐ์ฌ๋ฅผ ์ฝ์ด๋ณด์ธ์.
์ธ์ฌ์ดํธ ์ ์ฒด ์ฝ๊ธฐ
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
